Molecular and flow cytometric diagnostics for evaluation of therapy efficacy in myeloid leukemias
During the past decades, a lot of progress has been made in the treatment of acute and chronic myeloid leukemia. However, despite therapy, many patients experience relapse due to the presence of remaining leukemic cells, i.e. minimal residual disease (MRD). Our study contributed to the further identification of molecular MRD targets and showed that quantitative approaches (flow cytometry and molecular techniques) can be applied in routine clinical diagnostics to evaluate therapy efficacy and to guide therapeutic interventions in myeloid leukemia.
|Keywords||AML, CML, MRD, RQ-PCR, flow cytometric immunophenotyping|
|Promotor||Dongen, J.J.M. van (Jacques)|
|Sponsor||Dongen, Prof. Dr. J.J.M. van (promotor) , Vandenberghe, Prof. Dr. P. (promotor)|
Boeckx, N.. (2006, March 22). Molecular and flow cytometric diagnostics for evaluation of therapy efficacy in myeloid leukemias. Retrieved from http://hdl.handle.net/1765/7987